芝麻醇通过GLUT-4表达和改善胰腺活力来对抗阿托瓦斯塔丁的糖尿病效应
Raghuvir Keni1, Pawan Ganesh Nayak1, Nitesh Kumar1,2
1Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104 India.
3 Biotech
|October 27, 2023
概括
芝萨摩尔通过保护胰腺细胞免受阿托瓦斯塔丁诱导的亡而对抗他类药物相关的糖尿病. 虽然它改善了肌肉细胞GLUT-4,但它没有克服阿托瓦斯塔丁.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 尽管他类药物有好处,但与他类药物相关的糖尿病 (SAD) 是一个令人担忧的问题.
- 抑郁症的危险因素包括肥胖,久坐不动的生活方式和高血压.
- 了解SAD机制对于管理这种副作用至关重要.
研究的目的:
- 研究植物分子芝麻醇在对抗他类药物相关糖尿病方面的潜力.
- 探索芝麻醇对阿托瓦斯塔丁诱导的胰腺β细胞亡的保护作用.
- 评估芝麻醇对肌肉细胞中葡萄糖吸收和GLUT-4表达的影响.
主要方法:
- 用MIN-6和L6细胞系来研究阿托瓦斯塔丁和芝醇的影响.
- 在MMP测定和西部斑点分析中分析了亡途径和GLUT-4.
- 在体内研究中使用了饮食诱导的高胆固醇血症模型.
主要成果:
- 芝麻醇减轻了由阿托瓦斯塔丁诱导的胰腺β细胞亡.
- 芝麻醇增强了肌肉细胞中GLUT-4囊泡的产生.
- 芝麻醇没有逆转阿托瓦斯塔丁在肌肉细胞中抑制葡萄糖吸收的作用.
结论:
- 芝萨摩尔在抗击与他类药物相关的胰腺β细胞亡方面表现出潜力.
- 芝麻醇可以作为开发新策略的原型,用于对抗他类药物相关糖尿病.
- 对芝麻醇和类似化合物的进一步研究是合理的SAD管理.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
184
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
184
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
676
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
676
Oral Hypoglycemic Agents: Sulfonylureas
215
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
215


